We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

146 hedge funds and large institutions have $207M invested in Vanda Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 44 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more call options, than puts

Call options by funds: $261K | Put options by funds: $212K

20% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 44

0% more capital invested

Capital invested by funds: $206M → $207M (+$401K)

1.46% less ownership

Funds ownership: 75.45% → 74% (-1.5%)

4% less funds holding

Funds holding: 152 → 146 (-6)

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

Holders
146
Holders Change
-6
Holders Change %
-3.95%
% of All Funds
1.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
53
Reduced
44
Closed
25
Calls
$261K
Puts
$212K
Net Calls
+$49K
Net Calls Change
-$1.26M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$3.48M
2
BlackRock
BlackRock
New York
+$2.44M
3
SSA
Schonfeld Strategic Advisors
New York
+$1.3M
4
Millennium Management
Millennium Management
New York
+$1.29M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$7.47M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$4.61M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.23M
4
BCM
Bridgeway Capital Management
Texas
-$1.22M
5
BCM
BML Capital Management
Indiana
-$1.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$43.6M +$2.44M +508,597 +6%
Renaissance Technologies
2
Renaissance Technologies
New York
$18.5M -$757K -157,723 -4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$16.8M -$600K -125,002 -3%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$11.9M +$1.09M +227,428 +10%
TCM
5
Tang Capital Management
California
$11.3M – – –
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$9.1M – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$6.95M +$118K +24,483 +2%
Morgan Stanley
8
Morgan Stanley
New York
$6.42M +$3.48M +724,082 +117%
State Street
9
State Street
Massachusetts
$5.67M +$89.7K +18,681 +2%
Schroder Investment Management Group
10
Schroder Investment Management Group
United Kingdom
$4.96M – – –
Connor, Clark & Lunn Investment Management (CC&L)
11
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.92M +$185K +38,449 +5%
Goldman Sachs
12
Goldman Sachs
New York
$3.77M +$132K +27,459 +4%
Prudential Financial
13
Prudential Financial
New Jersey
$3.71M -$8.64K -1,800 -0.2%
Federated Hermes
14
Federated Hermes
Pennsylvania
$3.48M +$47.2K +9,840 +1%
Millennium Management
15
Millennium Management
New York
$3.2M +$1.29M +269,183 +67%
Charles Schwab
16
Charles Schwab
California
$2.67M -$181K -37,764 -6%
Northern Trust
17
Northern Trust
Illinois
$2.43M +$30.2K +6,283 +1%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$2.25M -$4.61M -959,807 -67%
MAM
19
Monaco Asset Management
Monaco
$1.88M +$907K +188,836 +93%
Citadel Advisors
20
Citadel Advisors
Florida
$1.83M +$1.15M +238,650 +168%
KAM
21
Krensavage Asset Management
New York
$1.81M -$172K -35,922 -9%
Wellington Management Group
22
Wellington Management Group
Massachusetts
$1.67M +$188K +39,195 +13%
JP Morgan Chase
23
JP Morgan Chase
New York
$1.61M +$840K +175,019 +109%
PIM
24
Profit Investment Management
Maryland
$1.58M – – –
SEI Investments
25
SEI Investments
Pennsylvania
$1.53M – – –
1
2 3 4 5

VNDA Hedge Fund Activity: Q4 2024 in Review

146 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2024, worth a combined $207M — up 0.19% from $206M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of VNDA and 21 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 53 added.

The largest buyer was Morgan Stanley, adding an estimated $3.48M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $7.47M sold.

  • 146 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2024, down from 152 in Q3 2024.
  • Funds reported $207M of Vanda Pharmaceuticals stock for Q4 2024, up 0.19% quarter-over-quarter.
  • 21 funds opened new Vanda Pharmaceuticals positions in Q4 2024 and 25 closed out, a net change of -4 holders.
  • The largest Vanda Pharmaceuticals buyer in Q4 2024 was Morgan Stanley, an estimated $3.48M added.
  • The largest Vanda Pharmaceuticals seller in Q4 2024 was Nantahala Capital Management, an estimated $7.47M sold.

Based on aggregated 13F filings for Q4 2024.